March 10, 2020 5:40pm
However, there still exists a level of market uncertainty, it’s time to buy cell and gene therapy equities especially if … they have announced Q4 and FY19 results
There will still be share pricing pain that will hopefully be weighed by forthcoming gains
The sector is what it is, until it isn’t and even then, it doesn’t seem to be … when you point one finger, there are three fingers pointing back at you!
The Dow closed UP +1167.14 points (+4.89%), the S&P closed UP +135.67 points (+4.94%) while the NASDAQ closed UP +393.58 points (+4.95%)
Indexes rose sharply in wild trading on Tuesday as investors weighed the prospects of fiscal stimulus to curb slower economic growth stemming from the coronavirus outbreak.
What a day, as the sector opened with an Advance/Decline (A/D) line of 22/13 followed by the 12 p.m. A/D line of 9/26 and then to finish the session at 24/10 and 1 flat.
Too much, too soon unless the supposed and projected stimulus meets expectation but, we all must be thankful that bottoms are potentially discovered.
Welcome to my world of defining the “grey’ in our universe!
Selling is NOT done YET!!
Thoughts to live by as far as BUYING is concerned: slow is smooth and smooth is fast!
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB closed up +2.31% and XBI closed up +2.26%
- Monday, the IBB closed down -6.80% and XBI closed down -8.06%
- Friday, the IBB closed down -1.53% and XBI closed down -2.50%
The advance/decline line scenario of 35 covered companies:
- Tuesday, the close was positive with an A/D line of 24/10, 1 flat of 35 covered;
- Monday, the close was negative with an A/D line of 3/32, 0 flat of 35 covered;
- Friday, the close was negative with an A/D line of 6/29, 2 flats of 35 covered;
Tuesday’s (highest 5) incliners:
- Mesoblast (MESO +$1.29);
- Intellia therapeutics (NTLA +$1.26);
- Ultragenyx (RARE +$3.53 after Monday’s -$4.67, Friday’s -$3.70 and Thursday’s -$2.08);
- Voyager therapeutics (VYGR +$0.66);
- Applied Genetic Technologies (AGTC +$0.20);
Tuesday’s (lowest 5) decliners:
- Alnylam Pharmaceuticals (ALNY -$0.57);
- Aduro Biotech (ADRO -$0.50);
- Biostage (BSTG -$0.38 after Monday’s +$0.02);
- AxoGen (AXGN -$0.35);
- Bellicum Pharmaceuticals (BLCM -$0.23);
The percentage (%) indicators:
- Tuesday’s the range of the 24-upside was +0.27% (FIXX) to +21.04% (MESO) while the 10-downside ranged from -0.20% (STML) to -16.29% (ADRO);
- Monday’s the range of the 3-upside was +0.53% (BSTG) to +16.53% (BSTG +$0.02) while the 30-downside ranged from -3.02% (ALNY) to -22.31% (PGEN);
- Friday’s the range of the 4-upside was +1.81% (IONS) to +12.2% (BCLI) while the 29-downside ranged from -0.50% (BLFS) to -10.68% (ADVM);
Upside volume stats: to compare
- Tuesday: 11 out of the 24-upside had higher than the 3-month average volume;
- Monday: 2 out of the 3-upside had higher than the 3-month average volume;
- Friday: 3 out of the 4-upside had higher than the 3-month average volume;
Downside volume stats:
- Tuesday: 5 out of the 10-downside had higher than the 3-month average volume;
- Monday: 24 out of the 32-downside had higher than the 3-month average volume;
- Friday: 13 out of the 29-downside had higher than the 3-month average volume;
1 flat - CLBS
Tuesday closed positive with 10 decliners, 24 advancers and 1 flat
Monday closed negative with 32 decliners, 3 advancers and 0 flats
Friday closed negative with 29 decliners, 4 advancers and 2 flats
Thursday closed negative with 24 decliners, 11 advancers and 2 flats
Wednesday closed positive with 3 decliners, 30 advancers and 2 flats
Tuesday closed negative with 26 decliners, 7 advancers and 2 flats
Monday closed positive with 11 decliners, 24 advancers and 0 flats
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.